

1 **Title**

2

3 **Full title:**

4 Antimicrobial use in laboratory rodent facilities in Australia and New Zealand- a cross-sectional
5 survey of veterinarians and facility managers

6

7 **Short title:**

8 Use of antimicrobials in laboratory rats and mice in Australia and New Zealand

9

10 **Authors:**

11 Rebecca S. Wilcox, Marc S. Marendá, Joanne M. Devlin[#] and Colin R. Wilks[#]

12 [#]These authors contributed equally

13 **Affiliations**

14 Rebecca S. Wilcox

15 **Roles:** Conceptualisation, Formal analysis, Investigation, Methodology, Writing – original draft,

16 Visualization, Corresponding author: rebecca.wilcox@rmit.edu.au

17

18 **Affiliations:** Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of

19 Science, The University of Melbourne, Parkville, Victoria, 3010, Australia

20 ORCID iD 0009-0004-9853-746X

21

22 Joanne M. Devlin

23 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Roles:** Formal analysis, Supervision, Writing – review & editing, Funding Acquisition

25 **Affiliations:** Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of

26 Science, The University of Melbourne, Parkville, Victoria, 3010, Australia,

27 ORCID iD 0000-0003-0400-9670

28

29 Marc S. Marendia

30

31 **Roles:** Formal analysis, Supervision, Writing – review & editing

32 **Affiliations:** Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of

33 Science, The University of Melbourne, Werribee, Victoria, 3030, Australia

34 ORCID iD: 0000-0001-6778-1110

35

36 Colin R. Wilks

37

38 **Roles:** Formal analysis, Supervision, Writing – review & editing

39 **Affiliations:** Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of

40 Science, The University of Melbourne, Parkville, Victoria, 3010, Australia

41

42 **Conflicts of Interest:**

43 The authors declare no conflicts of interest.

44

45 **Funding:**

46 Rebecca S. Wilcox is funded by a University of Melbourne Research Training Program Scholarship.

47

48

49 **Abstract**

50 This cross-sectional study surveyed veterinarians and facility managers to characterise the use of
51 antimicrobials in laboratory rodent facilities within Australia and New Zealand. Most facilities (71%)
52 reported routine administration of antimicrobials. The indications for antibiotic use reflected those
53 described in publications and differed significantly to reasons for use in non-laboratory animals .

54 Antimicrobials used include those of critical importance to human health, and access to these drugs is
55 unregulated, as prescription-only classes are ordered through research catalogues, without human or
56 veterinary physician prescriptions.

57 The ways in which antimicrobials are used in Australian and New Zealand rodent facilities are likely
58 contributing to antimicrobial resistance within rodent populations, particularly as they are largely
59 administered in drinking water, risking subtherapeutic dosing. Much antimicrobial use reported is
60 unnecessary and could be replaced with changes to husbandry and handling. The generation of
61 resistance in both pathogenic and commensal microbes may also represent a work health and safety
62 issue for humans working with these animals.

63 Reported disposal of antimicrobials included discharge into wastewater, without inactivation, and
64 some respondents reported disposal of substrate, or soiled bedding, nesting material, and disposable
65 enrichment items, from treated animals and medicated feed into landfill, without prior inactivation.

66 Environmental contamination with resistant microbes and antimicrobials is a significant driver of
67 antimicrobial resistance. As such, significant opportunities exist to implement judicious and
68 responsible use of antimicrobials within research rodent facilities in Australia and New Zealand, with
69 a particular focus on instituting aseptic surgery, optimising dosing regimens, and inactivation of
70 medicated water and substrate before disposal.

71

72 **Introduction**

73 Antimicrobial drug resistance (AMR) is a public health emergency and existential threat to the
74 advances in modern medicine of the last 80 years. AMR presently accounts for over seven million
75 deaths annually and is projected to cause ten million deaths by the year 2050 [1 - 3].

76

77 Bacterial resistance to antibiotics is inevitable, both spontaneously in nature, and in response to
78 exposure to antimicrobials. Resistance develops when microbes undergo mutation or exchange
79 resistance genes and is accelerated in the presence of antimicrobials [4]. To slow AMR, selective
80 pressures must be minimised through judicious use of antimicrobials [5].

81

82 Importantly, the pipeline for new antimicrobials is slow and has been unfruitful, due to stringent
83 regulatory requirements and low investment returns for pharmaceutical companies. Effective new
84 antimicrobials are used for short durations when compared with drugs for other conditions, and the
85 restricted use of newly approved antimicrobials further reduces the market share for investing
86 companies, along with the inevitable decline in their efficacy and value when AMR develops [6].

87 A comprehensive 'One Health' approach is essential for successful prevention and management of
88 numerous infectious diseases, including those caused by emerging pathogens and those due to AMR
89 [7, 8]. AMR has been described as the 'quintessential One Health issue' [9].

90 A One Health approach is essential to addressing AMR, given many human antimicrobials are also
91 used in veterinary medicine. There is evidence that some clinically relevant resistant bacteria and/or
92 their antimicrobial resistance genes (ARGs) readily transfer from bacteria present in animals to those
93 in humans [10, 11]. Recent studies have shown identical AMR signatures in pathogenic *Escherichia*
94 *coli* isolated from both humans and their companion animals, humans, and other species, and between
95 animals and the environment [12, 13].

96 Decades of injudicious antimicrobial use, in human and veterinary medicine, and in agriculture have
97 resulted in the development of extensive AMR in pathogenic and opportunistic microbes, resulting in
98 widespread morbidity and mortality. AMR bacteria are not necessarily more virulent, however, delays

99 in infection control due to ineffective initial treatment and testing required to determine appropriate
100 therapy, dramatically increases the cost of medical care, and impacts human and animal patients'
101 health [14].

102 Whilst the AMR implications of antimicrobial use in agriculture, aquaculture, companion animals and
103 equids are established and the subject of considerable quantitative and qualitative research, there is a
104 knowledge gap with respect to antimicrobial use in laboratory animals, particularly research rodents
105 [15-17]. This is important to understand, given the considerable number of research rodents used
106 worldwide, estimated to exceed 120 million, and their utility in biomedical research, meaning use has
107 only grown with time [18,19].

108 Resistant microbes pose significant zoonotic disease risks [20,21]. Veterinarians must consider the
109 impacts of antimicrobial use, administering them sparingly and appropriately, to safeguard the health
110 benefits to animals, preserve efficacy and minimise promotion of AMR [22]. This also applies to use
111 in research animals, and likewise, must be considered by animal researchers and laboratory animal
112 veterinarians [1].

113 This study aimed to investigate the use of antimicrobials in research rodent facilities in Australia and
114 New Zealand. Based on anecdotal observations and published research protocols, the authors
115 hypothesised that most research rodent facilities would report current antimicrobial use, with a high
116 prevalence of in-water administration and use of fluoroquinolone, tetracycline, and sulphonamide
117 classes. This cross-sectional study aimed to question these assumptions and characterise the means in
118 which antimicrobial containing substrates were disposed of, including wastewater, food, and bedding.
119 The study aimed to address the significant knowledge gap around antimicrobial use in laboratory
120 rodents, contributing to a missing component of the One Health paradigm in addressing AMR.

121

122 Prior to this survey there were no published data on the extent of antimicrobial use in rodent
123 laboratory facilities, in Australia and New Zealand, or globally.

124 **Materials and Methods**

125 The source population comprised the 158 eligible research rodent facilities across each of the states,
126 territories and islands of Australia and New Zealand, respectively. The total number of eligible
127 facilities was determined using a list provided by the Australia and New Zealand Laboratory Animal
128 Association (ANZLAA) Secretariat. The eligible respondent population comprised veterinarians and
129 animal facility managers, working in these facilities at the time of survey publication.

130

131 The study population was comprised of eligible respondents, answering the survey between February
132 2nd, 2020, to April 2nd, 2020. Respondents self-selected and the survey was distributed online using
133 the Qualtrics™ survey platform, through the ANZLAA members' email list. The survey is available
134 from the corresponding author.

135 The survey questions covered demographic aspects of respondents and the prevalence of
136 antimicrobial use, according to class, route and duration of administration, reasons for use and how
137 antimicrobials are sourced and disposed of. To be confident that the proportion of respondents giving
138 a particular answer was within a constant margin of error of 6.5% of a true prevalence of 50%, a total
139 of ninety-four (94) completed surveys were required. Sample size calculations were conducted with
140 finite population correction, and an assumption of 50% prevalence.

141

142 Data were analysed using a live excel calculator, from The Statistical Consulting Centre, University
143 of Melbourne, using a 95% confidence interval for a single population proportion, Θ , with a finite
144 population adjustment. The number of required responses was calculated using the Australian Bureau
145 of Statistics Sample Size Calculator.

146

147 Data were reported in proportions: the number of respondents selecting an answer or option were
148 divided by the total number of respondents attempting the question. Responses of 'do not know' and
149 unanswered questions were interpreted as missing values and were excluded from analysis. To
150 improve interpretation, or where there was redundancy, some response categories were merged. For
151 some complex questions, respondents provided replies in free text format.

152

153 The study was conducted according to the guidelines of the Declaration of Helsinki. The anonymous
154 online survey, recruitment text and accompanying Plain Language Statement were approved by the
155 Human Research Ethics Committee of the Faculty of Veterinary and Agricultural Science, The
156 University of Melbourne, Ethics ID Number 1955621.1. The Ethics Committee approved ‘Consent
157 being implied’, given, that to complete the survey, participants first read an Ethics approved Plain
158 Language Statement, that explained that all participant responses were anonymous, and could not be
159 re-identified, and that participation was voluntary.

160

161 **Results**

162 *Survey Response Rate and Respondent Occupation and Location*

163 Of the source population, comprising 158 eligible rodent facilities, there was a response rate of 60%
164 (95 respondents). Respondents were composed of 46% non-veterinarians with facility managerial
165 roles and 51% veterinarians in non-managerial roles. Three respondents (3%) did not report their
166 roles, though completed the survey, with other answers meeting eligibility criteria.

167 Eighty-two percent (82%) of respondents were from Australia and 18% from New Zealand.

168 *Facility Type and Housing*

169 Eighteen percent (18%) of respondents described facilities that met multiple criteria for facility type
170 and affiliation (**Fig 1**). Most respondents were from universities followed by private institutes.

171 Approximately half were associated with a human hospital, the majority, 60%, reporting facility co-
172 location within a human hospital. A small percentage were government facilities, or animal
173 production facilities or vendors.

174 **Figure 1.** *Types of Facilities Identified by Respondents (n=95) to a Survey Exploring Use of*
175 *Antimicrobials in Research Rodents in Australia and New Zealand*

176 *(TAFE - Technical and Further Education Institution)

177

178 Cage systems varied, with 24% using open-top conventional caging, 31% Physical Containment
179 Level (PC) 1, 86% PC2, and 15% PC3, and one third reported multiple caging systems, usually both
180 conventional open-top cages, and PC1 +/- PC2.

181

182 *Research Disciplines*

183 Most facilities (78%) reported research across multiple disciplines, including studies in: metabolic
184 disease (67%), neuroscience (55%), oncology (53%), cardiovascular disease (40%), the microbiome
185 (38%), infectious disease (37%), biologics and vaccine production (27%), and breeding of rodents for
186 commercial supply (12%). A third reported use for anatomy and physiology teaching purposes.

187

188 *Prevalence of Antimicrobial Use*

189 Seventy-one percent (71%) of rodent facilities reported routinely using antimicrobials, with an
190 identical prevalence across Australian and New Zealand respondents. Facilities associated with
191 human hospitals reported the greatest use of antimicrobials (79%), followed by 76% of university
192 respondents. Approximately two thirds (64%) of private institutes, and those without hospital or
193 university affiliation reported routine use. A third of the commercial animal breeding and supply
194 facilities reported routine use.

195

196 *Reasons for Use*

197 Most facilities reported multiple reasons for using antimicrobials, listed in **Table 1**. When used to
198 treat infections, one third of respondents (29%) reported routine use of microbial culture and
199 antimicrobial sensitivity testing (AST) to guide therapeutic decisions.

200 **Table 1.** *Reasons for Use of Antimicrobials Identified by Respondents (n = 95) to a Survey Exploring*
201 *Use of Antimicrobials in Research Rodents in Australia and New Zealand*

Reason for Use	Percentage of Respondents
Treating infections in individual animals	74%
Infection prevention in genetically immune-deficient rodents	58%
Prevention of infection at surgery	54%
Induction of genes (tetracycline promoters)	51%
Infection prevention post irradiation or chemotherapy	45%
Treatment of infections in rodent colonies	31%
Alteration of the microbiome	25%
Testing of antimicrobials	8%

202

203

204 *Routes of Administration*

205 Most respondents reported multiple routes of antimicrobial administration, most commonly in
206 drinking water (70%), commercially formulated chow (37%) or via injection (66%). Administration
207 via commercially formulated chow was common. The least prevalent routes were in-facility bespoke
208 addition of antimicrobials to powdered food, and subcutaneous insertion of antimicrobial releasing
209 devices or minipumps. See **Fig 2**.

210 **Figure 2.** *Route of Administration of Antimicrobials Identified by Respondents (n = 95) to a Survey*
211 *Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand*

212

213 *Prevalence of Usage According to Antimicrobial Class*

214 The fluoroquinolone class of antimicrobial was the most administered antimicrobial, with
 215 enrofloxacin the most prevalent specific antimicrobial used. Of the 67% of respondents administering
 216 enrofloxacin, which is light sensitive, in-water, only 48% reported covering medicated water bottles
 217 to prevent light exposure. Prevalence of antimicrobial use by class, route and duration of
 218 administration, and treatment of medicated water prior to disposal is listed in **Table 2**.

219

220 **Table 2.** *Prevalence of Antimicrobial Use Reported by Respondents (n = 95) from Rodent Research*
 221 *Facilities In Australia and New Zealand, According to Class, Route, Duration of Treatment, and*
 222 *Inactivation Treatment of Medicated Water Pre-disposal*

Antimicrobial Class	Proportion of Facilities	Route of Administration	Duration < 7 days	Duration > 7 days	Inactivation of Water Before Disposal
Fluoroquinolones e.g., enrofloxacin	79%	Injection – 74% In water – 67% Gavage/chow- 24%	63%	49%	19%
Tetracyclines e.g., doxycycline	61%	Chow* – 52% In water – 39% Injection – 18%	21%	79%	18%
Neomycin	56%	Topical – 61% In water – 39% Oral *– 10%	52%	48%	10%
Trimethoprim-sulphonamides	52%	In water – 52% Oral – 30% Injection – 44%	67%	50%	0

Amphenicols e.g., chloramphenicol	39%	Topical – 100%	95%	10%	N/A
Penicillins, e.g., amoxicillin, benzyl penicillin	36%	In water (amoxicillin)– 45% Injection (benzyl penicillin) – 75%	53%	58%	0
Polymyxins	35%	Topical -83% In water – 28% Injection – 11%	88%	35%	0
Glycopeptides e.g., vancomycin	13%	In water – 57% Gavage – 43% Injection – 29%	33%	67%	33%
Metronidazole	19%	In water – 20% Oral – 60% Injection – 30%	50%	50%	
Potentiated penicillins, e.g., amoxicillin-clavulanate	19%	Injection – 80% In water – 30% Oral – 20%	78%	30%	0
Cephalosporins, e.g., cefovecin	18%	Injection (3 rd generation) – 80% Oral (1 st generation)– 30%	89%	11%	N/A
Aminoglycosides	11%	In water – 50% Injection – 50% Oral – 17%	60%	40%	0

Antifungal azoles, e.g., itraconazole	11%	In water – 17% Oral - 17% Topical -67%	60%	40%	0
Macrolides, e.g., erythromycin	4%	In water – 50% Oral – 50%	0	100%	0
Lincosamides, e.g., clindamycin	2%	Injection – 50% Oral gavage – 50%	**	**	N/A
Amphotericin B	2%	In water – 100%	**	**	0

223

224 *Oral refers to oral gavage, except for tetracyclines and trimethoprim sulphonamides, where it is
225 mostly administered in commercially compounded rodent chow

226 ** not answered

227

228 *Co-administration of Antimicrobials*

229 Twenty-nine percent (29%) of respondents reported routinely co-administering multiple
230 antimicrobials. Given the multitude of combinations, free-text responses were requested, detailing
231 specific antimicrobial combinations. Examples of the free text responses are shown in **Fig 3**.

232 **Figure 3.** *Free Text Responses Describing Co-Administered Antimicrobials Reported by Respondents*
233 *(n = 95) from Rodent Research Facilities In Australia and New Zealand*

234

235 *Disposal of Antimicrobials*

236 Most facilities (81%) reported disposing medicated water, untreated, down the drain or sink. Those
237 inactivating the antimicrobials within the water reported using chemical or heat inactivation. A
238 minority engaged specialist contractors to dispose of water containing antimicrobials, see **Fig 4**.

239 **Figure 4.** *Management of Water Containing Antimicrobials before Disposal, Reported by*
240 *Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia*
241 *and New Zealand*

242

243 For antimicrobial treated rodent carcasses and their substrate, multiple means of disposal were
244 reported by individual facilities. Differing physical containment designations, corresponding to
245 degrees of biosecurity, of which most respondents had two or more designations, have specific legal
246 obligations regarding disposal, accounting for a range of disposal methods.

247

248 Respondents reported disposal of treated animal carcasses as follows: autoclaving or not autoclaving
249 carcasses followed by disposal via a medical waste contractor, 35% and 80% respectively; 4% via
250 incineration, 2% via landfill without prior autoclaving and 2% of respondents chose not to answer.

251 Bedding and substrate from treated animals were disposed of via a medical waste contractor (76%),
252 sent to land fill with no autoclaving (31%), or incinerated (2%), whilst 2% preferred not to answer.

253

254 Approximately one third of respondents (27%) reported disposing of medicated chow to land fill
255 without treatment. Most respondents used multiple disposal methods including specialised contractors
256 with or without prior autoclaving (87%) and incineration (3%) as per **Fig 5**.

257

258 **Figure 5.** *Methods of Disposal of Antimicrobial Containing Substrate: Medicated Animal Carcasses,*
259 *their Bedding and Medicated Food According to Respondents (n = 95) to a Survey Exploring Use of*
260 *Antimicrobials in Research Rodents in Australia and New Zealand*

261

262 *Sourcing of Antimicrobials*

263 Most facilities reported sourcing antimicrobials through multiple channels, including veterinary
264 wholesalers (93%), research chemical and reagent suppliers (41%), with a smaller number sourcing
265 from livestock food stores and online animal supply stores (4%), private veterinarians (4%),
266 compounding chemists (2%) and via food compounders with a veterinary script (2%), see **Fig 6**.

267

268 **Figure 6.** *Sources of Antimicrobials Identified by Respondents (n = 95) to a Survey Exploring Use of*
269 *Antimicrobials in Research Rodents in Australia and New Zealand*

270

271 In most cases multiple persons within facilities administered antimicrobials, including animal
272 technicians in 86% of facilities, researchers in 84%, and veterinarians in 75%. The use of
273 prescription-only antimicrobials was authorised by veterinarians in 83% of facilities, followed by
274 authorisation either or also via the Institutional Drugs and Poisons License Holder, (34%). In 17% of
275 facilities, prescription antimicrobials were used without veterinary prescription or direction, whilst 6%
276 of respondents reported that the Animal Ethics Committee (AEC) authorised their use.

277

278 *Standard Operating Procedures (SOPs) for Use and Disposal of Antimicrobials*

279 Over half of facilities (60%) had standardised protocols or SOPs, for the use of antimicrobials. The
280 remaining facilities did not (34%) or chose not to answer (6%). Twenty-four percent (24%) of
281 facilities had SOPs for disposal of antimicrobials, and 75% did not. One percent (1%) of respondents
282 chose not to answer.

283

284 **Discussion**

285 This survey shows that a wide range of antimicrobials are used in most rodent facilities in Australia
286 and New Zealand. They are used across a range of research types, and include several antimicrobial

287 classes, some of which are of critical importance to human health. The survey also highlights that the
288 common routes of administration and dosing may be inappropriate, and in general, inadequate
289 measures are taken to ensure the antimicrobials are not released in discarded solids and wastewater.

290

291 *Most Laboratory Rodent Facilities in Australia and New Zealand Use Antimicrobials*

292 The survey revealed a remarkable consistency of antimicrobial use in rodent facilities, across both
293 Australian and New Zealand, with an identical prevalence of 71%. This geographic homogeneity was
294 reflected across types of research reported, and classes of antimicrobials used. This data cannot be
295 compared with that from other regions, as there are no similar surveys or published data, to the
296 authors' knowledge. However, anecdotally, and as detailed in literature on laboratory animal medicine
297 and that describing contemporary research protocols, there is significant antimicrobial use, at
298 unquantified levels [25-27].

299

300 *Antimicrobials used include those of Critical Importance to Human Health and Access is Unregulated*

301 The survey documented administration of an extensive range of antimicrobial classes which differs
302 from that used by veterinarians in treating companion or agricultural animal species. The Australian
303 Strategic and Technical Advisory Group on Antimicrobial Resistance (ASTAG) has rated
304 antimicrobials used in humans, companion, and food production animals, and those used in both,
305 according to their importance in treating infections, and the severity of consequences should
306 resistance emerge or be amplified [49]. Antimicrobial use in the laboratory animal sector is not
307 included within ASTAG reviews [49].

308 There are no regulations for use in laboratory rodents and no antimicrobials registered for rodents. All
309 use is off label.

310 Several antimicrobials not used routinely in veterinary medicine, including those requiring
311 governmental authorisation in local human settings, such as vancomycin, colistin and ciprofloxacin,

312 (enrofloxacin being the veterinary drug that is metabolised to ciprofloxacin) are used commonly in
313 laboratory rodents, in Australia and New Zealand. Vancomycin and colistin are accessed through
314 research supply catalogues without prescription. In Australia and New Zealand, a veterinarian must
315 prescribe Schedule 4 (prescription animal remedy) antimicrobials for companion and food animals,
316 whereas this is not required for use in laboratory rodents [50].

317

318 *Antimicrobial Use Concur with that Described in Published Literature*

319 The reasons for antimicrobial use reported in the survey concur with published research protocols and
320 laboratory animal literature.

321

322 *Infection Prophylaxis in Immune Deficient Genetically Engineered Mouse Models*

323 The survey results mirror numerous publications detailing husbandry of immune deficient colonies,
324 with in-water administration of prophylactic antimicrobials, primarily enrofloxacin, sulphonamides,
325 and amoxicillin-clavulanate [1, 28, 29]. In Australia and New Zealand, enrofloxacin was the most
326 common choice, followed by trimethoprim-sulphonamide.

327

328 *Prophylaxis Around Time of Surgery*

329 Prophylactic use around surgery was reported commonly in the survey. Experimental surgery on
330 rodents is seldom performed by veterinarians or human surgeons. Surgeries are mostly undertaken by
331 researchers with little to no formal training in aseptic technique [30]. Lack of training may
332 unnecessarily inflate rates of post-operative infections and training in aseptic technique could obviate
333 such routine use [31, 32].

334

335 *Antibiotic Induction or Silencing of Gene Expression*

336 Tet-On/Tet-Off mice are a commonly used mouse model in which a gene expression system has been
337 inserted in the mouse genome. Gene expression can be turned ‘on’ or ‘off’ with tetracyclines in a
338 mouse’s food or water. A PubMed search with the term “Tet-on and Tet-off mice,” returns over
339 sixty-four million results, the model being used abundantly in biomedical research since its
340 introduction in 1992 [33]. Extensive use of this model in Australia and New Zealand, as reported,
341 coincides with the global literature.

342

343 *Prophylaxis in Whole Body Radiation and Bone Marrow Transplantation*

344 Bone marrow transplantation is commonly performed in mice, wherein they are subjected to whole
345 body ionising irradiation, allowing subsequent engraftment of donor bone marrow. Post-
346 transplantation, mice are immune compromised. Radiation damages the intestinal epithelium,
347 permitting intestinal bacteria to translocate into the bloodstream causing high morbidity and mortality.
348 Likewise, environmental microbes and pathogens cause opportunistic infections. Oral antimicrobials
349 prior to irradiation are used prophylactically in humans, as standard of care [34, 35]. Recent studies
350 have demonstrated in mice that similar reductions in infection are achieved with strict asepsis and use
351 of acidified water, rather than antimicrobials [36].

352 Global publications cite in-water or gavaged administration of metronidazole, neomycin,
353 ciprofloxacin and tetracyclines as prophylaxis [36]. Whilst the survey found high prevalence of use in
354 irradiated mice, enrofloxacin (precursor of ciprofloxacin) was used most frequently and usually
355 administered in water or by injection, not gavage.

356

357 *Induction of Microbiome Dysbiosis*

358 Microbiome research, the study of the complex consortia of microorganisms, their genes, and
359 interactions with the host is dramatically changing our understandings of medicine [37]. There is
360 growing interest in manipulation of the microbiome in mouse models to study its effects on health and

361 disease. This is mostly achieved with antimicrobials [38, 39]. A PubMed search on “microbiome
362 models in mice, using antimicrobials” returns over five million results.

363 Most published antibiotic-induced gut microbial imbalance or dysbiosis studies employ so-called
364 “cocktails” comprising combinations of vancomycin, neomycin, ampicillin, metronidazole,
365 polymyxins such as colistin sulphate, carbapenems, third generation cephalosporins and other drugs
366 [38]. One representative example prescribes: 6-8 weeks of ampicillin plus sulbactam, vancomycin,
367 ciprofloxacin, imipenem, and metronidazole administered *ad libitum* in the drinking water to mice
368 [40]. Most studies describe in-water administration [38, 41].

369 The data from this survey mirror such protocols, with respondents reporting administration of at least
370 three antimicrobials concurrently and in-water administration being most common.

371

372 *Management of Pathogens in Individual Rodents and Colonies*

373 Treatment of infections in individual rodents, as reported by three quarters of respondents, is
374 expected, being commonplace in veterinary medicine. A third of respondents reported treatment of
375 whole colony infections, which aligns with agricultural practices, such as mass in-water medication in
376 pigs and cattle [42, 43].

377 Antimicrobials are frequently used to suppress clinical illness or eradicate pathogens from rodent
378 colonies. Published protocols include elimination of *Helicobacter* spp. infection with medicated feed
379 containing amoxicillin, clarithromycin, and metronidazole; elimination of *Corynebacterium bovis* in
380 immune deficient mice with in-water amoxicillin clavulanate; enrofloxacin suppression of
381 *Rodentibacter pneumotropica* infection; and reduction of colony morbidity caused by *Pneumocystis*
382 spp. infection with trimethoprim/sulfamethoxazole [48].

383

384 *Much Antibiotic is Unjustified*

385 This survey reports frequent prophylactic use around the time of surgery, and in immune-
386 compromised rodent colonies. Infection can be avoided in these cases with institution of strict aseptic
387 practice and husbandry, the latter comprising specialised handling of mice, in laminar flow cabinets
388 with sterile gloves, and provision of sterilised food, bedding, acidified water etc.

389 Peri-surgical administration of antimicrobials has been considered 'the single most frequently abused
390 principle of veterinary surgery' [25]. Recent retrospective studies in laboratory rodents have found no
391 difference in post-operative infection rates in those animals not administered prophylactic
392 antimicrobials when there is adherence to aseptic technique [30, 51]. Literature in human medicine
393 demonstrates that antimicrobial prophylaxis is unnecessary [52]. With exceptions, such as
394 orthopaedic, neurological, implant and gastrointestinal surgery, surgeons are encouraged to avoid
395 routine perioperative antibiotics [53, 54].

396 Opportunistic infections in immune compromised mice may be prevented with aseptic husbandry
397 techniques, and use of sterile bedding, food, and acidified or sterilised water [36].

398 Routine antibiotic administration in immune deficient animals may result in superinfection, as
399 evidenced in nude rats administered months of antimicrobials, of multiple classes, to suppress
400 *Rodentibacter* infection. These rats had never tested positive to *Klebsiella pneumoniae*, yet this
401 pathogen arose within the colony and was extensively drug resistant following antibiotics [55]. The
402 *Rodentibacter* infection recurred once antimicrobials were discontinued.

403

404 *The Majority of Reported Antimicrobial Use is Delivering Subtherapeutic Doses*

405 The administration of insufficient antibiotic doses, being subtherapeutic for treating infection, induces
406 antibiotic resistance [56]. In rodent facilities, decision on the route of administration is often
407 influenced by labour requirements [57]. Handling of individual rodents when it is necessary to
408 administer medications to a whole colony is time consuming, expensive and requires technical
409 expertise and attention to aseptic husbandry [58]. Consequently, in-water administration is the
410 commonly described route in publications and was reported by most survey respondents.

411 Such mass treatment is problematic because it cannot be assured that all animals will consume
412 sufficient water to receive an appropriate dose of antimicrobial. Also, many antimicrobials are
413 unstable in water, or when exposed to light, including doxycycline and enrofloxacin [59, 60]. Fewer
414 than half of survey respondents covered water bottles containing these antimicrobials, thus reducing
415 the delivered dose.

416 This survey also documented a high prevalence of cefovecin administration by injection. Therapeutic
417 plasma concentrations in mice are unachievable with cefovecin, as the drug's half-life in mice is 50
418 minutes, compared to 7-14 days for cats and dogs, for whom it is registered [61].

419

420 *Reported Use May Represent a Risk to Human and Rodent Health*

421 Numerous studies in rodents have found emergence of resistant gut microbiota, even with a single
422 class and dose of antimicrobial [62]. These data suggest that oral administration of antimicrobials, in
423 laboratory rodents, have pronounced and long-standing effects on resistance gene amplification and
424 *de novo* development in gut microbiota [63, 64].

425 Microbial cross-resistance to multiple antimicrobial classes, conferred by a common molecular
426 mechanism, may arise following administration of a single class [65, 66]. Administration of a broad
427 range of antibiotic classes, as reported in this survey, is likely inducing multi-species microbial cross-
428 resistance.

429 Resistant microbes are transferred vertically, from rodent dams to offspring during parturition and
430 nursing. Resistance selected for in the microbiota, by antimicrobial administration, may be transmitted
431 indefinitely through generations of animals, as rodent pups acquire their microbiome from their dam
432 and the environment [67, 68]. Mouse-adapted *S. aureus* has been vertically transmitted in mouse
433 colonies for generations [69].

434 There are numerous examples of cross infection between methicillin resistant *S. aureus* (MRSA)
435 between humans and house mice and rats, and recent documentation of cross-transmission of

436 pathogenic and multidrug resistant (MDR) resistant *E. coli* between humans and companion animals
437 [70-73].

438 A study across German research animal facilities compared microbiome profiles from the intestines of
439 research rodents, and the skin of personnel working with these animals. Genomic sequencing found
440 that shed skin or dust particles carried by either animals, care takers, or scientists influenced and was
441 shared by the gastrointestinal microbiota of research mice. This demonstrated that despite standard
442 biosecurity engineering controls of humans wearing masks, gowns and gloves in the facility, there is a
443 significant transfer and sharing of skin microbiota from humans to research rodents. It is plausible that
444 the converse applies, and the rodent microbiome from the gut or skin, can transfer to humans [23, 24,
445 74]. Another study isolated a human strain of MDR *C. difficile* from an outbreak in a mouse facility,
446 co-located with a human hospital. The authors proposed that the AMR accrued through rodent
447 exposure to antimicrobials and horizontal gene transfer, from commensals to the *Clostridia*. The
448 outbreak was facility wide, despite the work occurring in rooms with high level biosecurity [75, 76].

449 These examples underscore the fact that laboratory rodents and facilities may harbour dangerous
450 microbes, functioning as a reservoir for resistant pathogens and genes. This is a particular issue in
451 human healthcare settings, and half of survey respondents reported their co-location with human
452 hospitals.

453 Induction of resistance in rodent pathogens, through unnecessary and subtherapeutic dosing, will also
454 compromise animal welfare, rendering bacterial infections more difficult to treat.

455 These factors are important to consider given the rodent housing systems documented by respondents.
456 Specifically, conventional open-top cages were common across all facilities, and these generate
457 significant particulate contamination of air, which is then shared between rodent cages, and personnel
458 working the facilities are exposed to particulates, through direct contact and inhalation. During cage
459 washing of PC1 and PC2 cages, staff are likewise, exposed to these aerosols. Sharing of air and
460 particulates is an established work health and safety issue in all rodent facilities below PC3
461 biocontainment level. Lab animal allergy is a proxy. This is a condition arising from unavoidable

462 exposure of personnel to particulate matter (rodent dander) in the air, via inhalation or direct contact,
463 regardless of cage types and engineering controls [88].

464

465 *Disposal of Antimicrobials in Laboratory Rodent Waste is Causing Environmental Contamination*
466 *which may Contribute to AMR.*

467 This survey showed that antimicrobial containing water is disposed of untreated by most facilities. A
468 third of facilities administering medicated chow dispose of it untreated, in regular municipal waste,
469 where it may contaminate the environment and be consumed by animals. Some facility waste
470 substrates, including bedding of antimicrobial treated animals, containing urine and faeces, also are
471 disposed of without treatment. Such practices risk contaminating the environment with antimicrobials,
472 and microbes that may contain ARGs.

473 The spread of drug resistance genes has been classified as new type of environmental pollutant [77].
474 Microbial exposure to anthropogenic antimicrobials in wastewater, agricultural settings, or the built
475 environment, may select for AMR in the environmental resistome, generating reservoirs of resistant
476 pathogens and microbial reservoirs of ARGs [78, 79].

477 Hospital and laboratory wastewater are established contributors to AMR and release of ARGs to the
478 environment, underscoring the need for efforts to treat water pre-disposal [80-82]. Recent reviews
479 have identified the significant and overlooked contribution of inappropriately disposed of
480 antimicrobials as drivers of AMR in both human and veterinary medicine [83]. Whilst there is some
481 guidance around disposal of laboratory waste that contains antimicrobials, there are no equivalent
482 publicly available recommendations for laboratory *animal* waste containing antimicrobials [84].

483 Antimicrobials, most commonly reported in the survey, have long-standing environmental impacts.
484 Enrofloxacin is a stable antimicrobial pollutant with a half-life as long as 3–9 years in natural
485 environments [85]. Tetracycline containing rodent chow, commonly used by survey respondents, is
486 largely disposed of untreated in municipal landfill. Wild birds and rodents consuming the chow from
487 landfill may disseminate antimicrobial resistant microbes and their ARGs to human and other animal

488 populations. Studies demonstrate aerosolization and dissemination of resistant microbes and ARGs
489 during routine passage of waste through transfer stations, risking the health and safety of waste
490 workers and people living proximal to municipal landfill [86, 87].

491

492 **Conclusion**

493 In summary, this survey characterises and quantifies, for the first time, the extent of the use of
494 antimicrobials in research rodent facilities in Australia and New Zealand. The data align with
495 laboratory rodent literature describing regimens and protocols for antimicrobial use within research
496 projects. We believe this is the first published quantitative, and qualitative survey of its type, globally,
497 characterising prevalence of use, indications for and regimens of administration, means of access, and
498 common modes of disposal of antimicrobials, administered to laboratory rodents.

499 The survey identified areas where antimicrobial use is not indicated, and is injudicious, as well as
500 confirming its widespread use, inherent to rodent research models, as researchers apply published
501 consensus antimicrobial protocols. The imprudent use reported, including commonplace
502 subtherapeutic dosing and administration of antimicrobials of critical importance to human health, and
503 inappropriate disposal, is likely contributing to the emergence of AMR in laboratory rodents, in the
504 environment and potentially, in persons working with the animals. This is particularly concerning
505 where the rodent facility is collocated with a hospital since there will be many opportunities for
506 transfer on personnel who move between the animal facility and the hospital if inadvertent breaches of
507 biosecurity occur.

508 Inappropriate or imprudent use of antimicrobials also has negative implications for the research
509 rodents, which may develop untreatable infections, as well as impacts for public health at a facility
510 and environmental level. The survey has identified an urgent need to develop and implement
511 evidence-based standard operating principles for responsible antimicrobial usage and disposal in
512 rodent research facilities, in Australia and New Zealand.

513

514 **Acknowledgments**

515 We would like to express our gratitude to the laboratory animal community in Australia and New
516 Zealand, for their voluntary participation in the survey. We also wish to thank the ANZLAA
517 Secretariat for providing the contact details of all laboratory animal facilities in these countries. We
518 would also like to acknowledge the support provided by the Statistical Consulting Centre, The
519 University of Melbourne, for assistance with data analysis.

520

521 **References**

522

- 523 1. Narver HL. Antimicrobial stewardship in laboratory animal facilities. Journal of the American
524 Association for Laboratory Animal Science : JAALAS [Internet]. 2017 ;56(1) :6-10.
- 525 2. Yadav S, Kapley A. Antibiotic resistance: Global health crisis and metagenomics. Biotechnol Rep
526 (Amst) [Internet]. 2021 Feb 23;29:e00604.
- 527 3. Tomczyk S, Taylor A, Brown A, de Kraker MEA, El-Saed A, Alshamrani M, Hendriksen RS,
528 Jacob M, Löfmark S, Perovic O, Shetty N, Sievert D, Smith R, Stelling J, Thakur S, Vietor AC,
529 Eckmanns T, WHO AMR Surveillance and Quality Assessment Collaborating, Centres Network.
530 Impact of the COVID-19 pandemic on the surveillance, prevention, and control of antimicrobial
531 resistance: A global survey. J Antimicrob Chemother [Internet]. 2021 Oct 11;76(11):3045-58.
- 532 4. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr [Internet]. 2016 Apr
533 ;4(2) : 10.1128/microbiolspec.VMBF-2015.
- 534 5. Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M.
535 Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health.
536 Infect Drug Resist [Internet]. 2020 Dec 29;13:4713-38.

- 537 6. Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how
538 new antibiotics are reimbursed: Development of an insurance framework for new antibiotics based on
539 a policy of risk mitigation. *Health Policy* [Internet]. 2017 Oct;121(10):1025-30.
- 540 7. Velazquez-Meza M, Galarde-López M, Carrillo-Quiróz B, Alpuche-Aranda C. Antimicrobial
541 resistance: One health approach. *Veterinary world* [Internet]. 2022;15; 2022/03/28(3):743-9.
- 542 8. Guardabassi L, Butaye P, Dockrell DH, Fitzgerald JR, Kuijper EJ; ESCMID Study Group for
543 Veterinary Microbiology (ESGVM). One Health: a multifaceted concept combining diverse
544 approaches to prevent and control antimicrobial resistance. *Clin Microbiol Infect*. 2020
545 Dec;26(12):1604-1605. doi: 10.1016/j.cmi.2020.07.012. Epub 2020 Jul 20. PMID: 32702500.
- 546 9. Robinson TP, Bu DP, Carrique-Mas J, Fèvre EM, Gilbert M, Grace D, Hay SI, Jiwakanon J,
547 Kakkar M, Kariuki S, Laxminarayan R, Lubroth J, Magnusson U, Thi Ngoc P, Van Boeckel TP,
548 Woolhouse MEJ. Antibiotic resistance is the quintessential one health issue. *Trans R Soc Trop Med*
549 *Hyg* [Internet]. 2016 Jul;110(7):377-80.
- 550 10. Kim Y, Leung MHY, Kwok W, Fournié G, Li J, Lee PKH, Pfeiffer DU. Antibiotic resistance gene
551 sharing networks and the effect of dietary nutritional content on the canine and feline gut resistome.
552 *Animal Microbiome* [Internet]. 2020;2(1):4.
- 553 11. Røken M, Forfang K, Wasteson Y, Haaland AH, Eiken HG, Hagen SB, Bjelland AM.
554 Antimicrobial resistance-do we share more than companionship with our dogs? *J Appl Microbiol*
555 [Internet]. 2022 Aug;133(2):1027-39.
- 556 12. Ogura Y, Ueda T, Nukazawa K, Hiroki H, Xie H, Arimizu Y, Hayashi T, Suzuki Y. The level of
557 antimicrobial resistance of sewage isolates is higher than that of river isolates in different *escherichia*
558 *coli* lineages. *Sci Rep* [Internet]. 2020 Oct 21;10(1):17880-x.
- 559 13. Elankumaran P, Cummins ML, Browning GF, Marena MS, Reid CJ, Djordjevic SP. Genomic
560 and temporal trends in canine ExPEC reflect those of human ExPEC. *Microbiol Spectr* [Internet].
561 2022 Jun 29;10(3):e0129122,22. Epub 2022 Jun 8.

- 562 14. Dadgostar P. Antimicrobial Resistance: Implications and Costs. *Infect Drug Resist.* 2019 Dec
563 20;12:3903-3910. doi: 10.2147/IDR.S234610. PMID: 31908502; PMCID: PMC6929930.
- 564 15. Marta-Costa A, Miranda C, Silva V, Silva A, Martins Â, Pereira JE, Maltez L, Capita R, Alonso-
565 Calleja C, Igrejas G, Poeta P. Survey of the knowledge and use of antibiotics among medical and
566 veterinary health professionals and students in portugal. *Int J Environ Res Public Health* [Internet].
567 2021 Mar 9;18(5):2753. doi: 10.3390/ijerph18052753.
- 568 16. Pleydell EJ, Souphavanh K, Hill KE, French NP, Prattley DJ. Descriptive epidemiological study
569 of the use of antimicrobial drugs by companion animal veterinarians in new zealand. *N Z Vet J*
570 [Internet]. 2012 Mar;60(2):115-22.
- 571 17. Kalnins NJ, Croton C, Haworth M, Gibson J, Purcell SL, Stewart AJ. A VetCompass Australia
572 study of antimicrobial use in dog-to-dog bite wounds (1998-2018). *Antibiotics* (Basel, Switzerland)
573 [Internet]. 2022;11(1):55.
- 574 18. Cait J, Cait A, Scott RW, Winder CB, Mason GJ. Conventional laboratory housing increases
575 morbidity and mortality in research rodents: Results of a meta-analysis. *BMC Biol* [Internet]. 2022
576 Jan 13;20(1):15-0.
- 577 19. Bryda EC. The mighty mouse: The impact of rodents on advances in biomedical research. *Mo
578 Med* [Internet]. 2013;110(3):207-11.
- 579 20. Angulo FJ, Nargund VN, Chiller TC. Evidence of an association between use of anti-microbial
580 agents in food animals and anti-microbial resistance among bacteria isolated from humans and the
581 human health consequences of such resistance. *J Vet Med B Infect Dis Vet Public Health.* 2004 Oct-
582 Nov;51(8-9):374-9. doi: 10.1111/j.1439-0450.2004.00789.x. PMID: 15525369.
- 583 21. Meade E, Savage M, Slattery M, Garvey M. Investigation of Alternative Therapeutic and Biocidal
584 Options to Combat Antifungal-Resistant Zoonotic Fungal Pathogens Isolated from Companion
585 Animals. [Internet]. ; 2021 DOI: 10.3390/idr13020034

- 586 22. Weese JS, Giguère S, Guardabassi L, Morley PS, Papich M, Ricciuto DR, Sykes JE. ACVIM
587 consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. *J Vet*
588 *Intern Med* [Internet]. 2015;29(2):487-98.
- 589 23. Raafat D, Mrochen DM, Al'Sholui F, Heuser E, Ryll R, Pritchett-Corning KR, Jacob J, Walther B,
590 Matuschka FR, Richter D, Westerhüs U, Pikula J, van den Brandt J, Nicklas W, Monecke S,
591 Strommenger B, van Alen S, Becker K, Ulrich RG, Holtfreter S. Molecular epidemiology of
592 methicillin-susceptible and methicillin-resistant staphylococcus aureus in wild, captive and laboratory
593 rats: Effect of habitat on the nasal *S. aureus* population. *Toxins (Basel)* [Internet]. 2020 Jan
594 24;12(2):80. doi: 10.3390/toxins12020080.
- 595 24. Sakr A, Brégeon F, Mège J, Rolain J, Blin O. Staphylococcus aureus nasal colonization: An
596 update on mechanisms, epidemiology, risk factors, and subsequent infections. *Frontiers in*
597 *microbiology* [Internet]. 2018;9:2419.
- 598 25. Morris TH. Antibiotic therapeutics in laboratory animals. *Lab Anim* [Internet]. 1995 Jan;29(1):16-36.
- 599 26. Burkholder T, Foltz C, Karlsson E, Linton CG, Smith JM. Health evaluation of experimental
600 laboratory mice. *Current protocols in mouse biology* [Internet]. 2012;2:145-65.
- 601 27. Michaud CR, Qin J, Elkins WR, Gozalo AS. Comparison of 3 topical treatments against ulcerative
602 dermatitis in mice with a C57BL/6 background. *Comp Med* [Internet]. 2016;66(2):100-4.
- 603 28. A ryee K, Shultz LD, Brehm MA. Immunodeficient mouse model for human hematopoietic stem cell
604 engraftment and immune system development. *Methods Mol Biol* [Internet]. 2014;1185:267-78.
- 605 29. Pearson EC, Pugazhenthii U, Fong DL, Smith DE, Nicklawsky AG, Habenicht LM, Fink MK,
606 Leszczynski JK, Schurr MJ, Manuel CA. Metaphylactic antibiotic treatment to prevent the transmission of
607 corynebacterium bovis to immunocompromised mouse offspring. *J Am Assoc Lab Anim Sci* [Internet].
608 2020 Nov 1;59(6):712-8.
- 609 30. Pritchett-Corning K, Luo Y, Mulder GB, White WJ. Principles of rodent surgery for the new surgeon.
610 *Journal of visualized experiments : JoVE* [Internet]. 2011(47):2586.

- 611 31. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and
612 heterotopic human pancreatic cancer xenografts in immunodeficient mice. *Nat Protoc* [Internet].
613 2009;4(11):1670-80.
- 614 32. Yaltirik M, Dedeoglu K, Bilgic B, Koray M, Ersev H, Issever H, Dulger O, Soley S. Comparison
615 of four different suture materials in soft tissues of rats. *Oral Dis*. 2003 Nov;9(6):284-6. doi:
616 10.1034/j.1601-0825.2003.00954.x. PMID: 14629327.
- 617 33. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive
618 promoters. *Proc Natl Acad Sci U S A* [Internet]. 1992 Jun 15;89(12):5547-51.
- 619 34. Seo SK, Xiao K, Huang Y, Jongwutiwes U, Chung D, Maloy M, Giralt S, Barker JN, Jakubowski AA,
620 Papanicolaou GA. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of
621 bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution
622 study. *J Infect* [Internet]. 2014 ;69(4) :341-51.
- 623 35. Guiot HF, van Furth R. Selective decontamination in bone marrow transplant recipients. *Epidemiol
624 Infect* [Internet]. 1992 Dec;109(3):349-60.
- 625 36. Duran-Struuck R, Dysko RC. Principles of bone marrow transplantation (BMT): Providing optimal
626 veterinary and husbandry care to irradiated mice in BMT studies. *J Am Assoc Lab Anim Sci* [Internet].
627 2009 Jan;48(1):11-22.
- 628 37. Cullen CM, Aneja KK, Beyhan S, Cho CE, Woloszynek S, Convertino M, McCoy SJ, Zhang Y,
629 Anderson MZ, Alvarez-Ponce D, Smirnova E, Karstens L, Dorrestein PC, Li H, Sen Gupta A, Cheung K,
630 Powers JG, Zhao Z, Rosen GL. Emerging priorities for microbiome research. *Front Microbiol* [Internet].
631 2020 Feb 19;11:136.
- 632 38. Kennedy EA, King KY, Baldrige MT. Mouse microbiota models: Comparing germ-free mice and
633 antibiotics treatment as tools for modifying gut bacteria. *Front Physiol* [Internet]. 2018 Oct 31;9:1534.
- 634 39. Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of
635 intestinal microbiota and bile acid profile in mice. *Toxicol Appl Pharmacol* [Internet]. 2014;277(2):138-45.

- 636 40. Fiebiger U, Bereswill S, Heimesaat MM. Dissecting the interplay between intestinal microbiota and
637 host immunity in health and disease: Lessons learned from germfree and gnotobiotic animal models.
638 European journal of microbiology & immunology [Internet]. 2016;6(4):253-71.
- 639 41. Ericsson AC, Franklin CL. Manipulating the gut microbiota: Methods and challenges. ILAR journal
640 [Internet]. 2015 ;56(2) :205-17.
- 641 42. Little S, Woodward A, Browning G, Billman-Jacobe H. In-water antibiotic dosing practices on pig
642 farms. Antibiotics [Internet]. 2021;10(2)
- 643 43. Cusack P. Evaluation of practices used to reduce the incidence of bovine respiratory disease in
644 australian feedlots (to november 2021). Aust Vet J [Internet]. 2023 Mar 30
- 645 44. Pearson EC, Pugazhenthii U, Fong DL, Smith DE, Nicklawsky AG, Habenicht LM, Fink MK,
646 Leszczynski JK, Schurr MJ, Manuel CA. Metaphylactic antibiotic treatment to prevent the transmission of
647 corynebacterium bovis to immunocompromised mouse offspring. J Am Assoc Lab Anim Sci [Internet].
648 2020 Nov 1;59(6):712-8.
- 649 45. Jury J, Gee LC, Delaney KH, Perdue MH, Bonner RA. Eradication of helicobacter spp. from a rat
650 breeding colony. Contemp Top Lab Anim Sci [Internet]. 2005 Jul;44(4):8-11.
- 651 46. Kerton A, Warden P. Review of successful treatment for helicobacter species in laboratory mice. Lab
652 Anim [Internet]. 2006 Apr;40(2):115-22.
- 653 47. Towne JW, Wagner AM, Griffin KJ, Buntzman AS, Frelinger JA, Besselsen DG. Elimination of
654 pasteurella pneumotropica from a mouse barrier facility by using a modified enrofloxacin treatment
655 regimen. Journal of the American Association for Laboratory Animal Science : JAALAS [Internet]. 2014
656 ;53(5) :517-22.
- 657 48. Weisbroth SH. Pneumocystis: Newer knowledge about the biology of this group of organisms in
658 laboratory rats and mice. Lab Anim (NY) [Internet]. 2006 Oct;35(9):55-61.
- 659 49. Sri A, Bailey KE, Gilkerson JR, Browning GF, Hardefeldt LY. Attitudes towards use of high-
660 importance antimicrobials-A cross-sectional study of Australian veterinarians. Antibiotics (Basel)
661 [Internet]. 2022 Nov 10;11(11):1589. doi: 10.3390/antibiotics11111589.

- 662 50. Dyke TM. Regulation of veterinary antibiotics in Australia. *Commun Dis Intell Q Rep*. 2003;27
663 Suppl:S6-8. PMID: 12807266.
- 664 51. Moats C, Cook K, Armantrout K, Crank H, Uttke S, Maher K, Bochart RM, Lawrence G, Axthelm
665 MK, Smedley JV. Antimicrobial prophylaxis does not improve post-surgical outcomes in SIV/SHIV-
666 uninfected or SIV/SHIV-infected macaques (*macaca mulatta* and *macaca fascicularis*) based on a
667 retrospective analysis. *PLoS One* [Internet]. 2022 Apr 20;17(4):e0266616.
- 668 52. Giguere, G, Walker, RD, Giguere, S, Prescott, JF, Baggot, JD, Walker, RD, Dowling, PM.
669 Antimicrobial prophylaxis for surgery. [Internet]. Ames, Iowa: Blackwell Publishing; 2006. 340 p
- 670 53. Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: Clean non-implant wounds. *J*
671 *Chemother* [Internet]. 2001 Nov;13 Spec No 1(1):96-101.
- 672 54. Hasan GZ, Saleh FM, Hossain MZ, Amin MR, Siddiqui TH, Islam MD, Chakraborty S. Antibiotic
673 prophylaxis is unnecessary in clean surgery. *Mymensingh Med J* [Internet]. 2013 Apr;22(2):342-4. 4
- 674 55. Hansen AK. Antibiotic treatment of nude rats and its impact on the aerobic bacterial flora. *Lab Anim*
675 [Internet]. 1995 Jan;29(1):37-44.
- 676 56. Viswanathan VK. Off-label abuse of antibiotics by bacteria. *Gut Microbes* [Internet]. 2014;5(1):3-4.
- 677 57. Nunamaker EA, Artwohl JE, Anderson RJ, Fortman JD. Endpoint refinement for total body irradiation
678 of C57BL/6 mice. *Comp Med* [Internet]. 2013 Feb;63(1):22-8.
- 679 58. Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. *Contemp Top Lab*
680 *Anim Sci* [Internet]. 2004 Nov;43(6):42-51.
- 681 59. Redelsperger IM, Taldone T, Riedel ER, Lephherd ML, Lipman NS, Wolf FR. Stability of Doxycycline
682 in Feed and Water and Minimal Effective Doses in Tetracycline-Inducible Systems. *J Am Assoc Lab*
683 *Anim Sci*. 2016;55(4):467-74. PMID: 27423155; PMCID: PMC4943619.
- 684 60. Marx JO, Vudathala D, Murphy L, Rankin S, Hankenson FC. Antibiotic administration in the drinking
685 water of mice. *J Am Assoc Lab Anim Sci* [Internet]. 2014 May;53(3):301-6.

- 686 61. Sanders KL, Bas E, Cox SK, Rothen DE. Pharmacokinetics of single-bolus subcutaneous cefovecin in
687 C57BL/6 mice. *Journal of the American Association for Laboratory Animal Science : JAALAS* [Internet].
688 2017 ;56(5) :558-61.
- 689 62. Korry BJ, Cabral DJ, Belenky P. Metatranscriptomics reveals antibiotic-induced resistance gene
690 expression in the murine gut microbiota. *Frontiers in microbiology* [Internet]. 2020;11:322.
- 691 63. de Nies L, Busi SB, Tsenkova M, Halder R, Letellier E, Wilmes P. Evolution of the murine gut
692 resistome following broad-spectrum antibiotic treatment. *Nature Communications* [Internet]. 2022 ;13(1)
693 :2296.
- 694 64. Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly
695 influence the levels of antibiotic resistance in gut microbiota. *Antimicrob Agents Chemother* [Internet].
696 2013 Aug;57(8):3659-66.
- 697 65. Colclough A, Corander J, Sheppard SK, Bayliss SC, Vos M. Patterns of cross-resistance and collateral
698 sensitivity between clinical antibiotics and natural antimicrobials. *Evolutionary applications* [Internet].
699 2019;12(5):878-87.
- 700 66. Shu C, Chen W, Chang Y, Chen J, Liu F, Huang Y, You C, Wu EH. Exposure to one antibiotic leads
701 to acquisition of resistance to another antibiotic via quorum sensing mechanisms. *Frontiers in*
702 *Microbiology* [Internet]. 2021;11
- 703 67. Klassert TE, Zubiria-Barrera C, Kankel S, Stock M, Neubert R, Lorenzo-Diaz F, Doehring N, Driesch
704 D, Fischer D, Slevogt H. Early bacterial colonization and antibiotic resistance gene acquisition in
705 newborns. *Front Cell Infect Microbiol* [Internet]. 2020 Jul 10;10:332.
- 706 68. Patangia DV, Ryan CA, Dempsey E, Stanton C, Ross RP. Vertical transfer of antibiotics and antibiotic
707 resistant strains across the mother/baby axis. *Trends Microbiol* [Internet]. 2022 ;30(1) :47-56.
- 708 69. Schulz D, Grumann D, Trübe P, Pritchett-Corning K, Johnson S, Reppschläger K, Gumz J,
709 Sundaramoorthy N, Michalik S, Berg S, van den Brandt J, Fister R, Monecke S, Uy B, Schmidt F, Bröker
710 B,M., Wiles S, Holtfreter S. Laboratory mice are frequently colonized with staphylococcus aureus and

- 711 mount a systemic immune response-note of caution for in vivo infection experiments. *Frontiers in cellular*
712 *and infection microbiology* [Internet]. 2017;7:152
- 713 70. Gwenzi W, Chaukura N, Muisa-Zikali N, Teta C, Musvuugwa T, Rzymiski P, Abia ALK. Insects,
714 rodents, and pets as reservoirs, vectors, and sentinels of antimicrobial resistance. *Antibiotics* (Basel,
715 Switzerland) [Internet]. 2021;10(1):68.
- 716 71. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant bacteria. *J*
717 *Antimicrob Chemother* [Internet]. 2004 Aug;54(2):321-32.
- 718 72. Argudín MA, Deplano A, Meghraoui A, Dodémont M, Heinrichs A, Denis O, Nonhoff C, Roisin S.
719 Bacteria from animals as a pool of antimicrobial resistance genes. *Antibiotics* [Internet]. 2017;6(2)
- 720 73. Pomba C, Rantala M, Greko C, Baptiste KE, Catry B, van Duijkeren E, Mateus A, Moreno MA,
721 Pyörälä S, Ružauskas M, Sanders P, Teale C, Threlfall EJ, Kunsagi Z, Torren-Edo J, Jukes H, Törneke K.
722 Public health risk of antimicrobial resistance transfer from companion animals. *J Antimicrob Chemother*
723 [Internet]. 2017 Apr 1;72(4):957-68.
- 724 74. Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, Gläsner J, Gopalakrishnan S, Grassl GA,
725 Günther C, Haller D, Hirose M, Ibrahim S, Loh G, Mattner J, Nagel S, Pabst O, Schmidt F, Siegmund B,
726 Strowig T, Volynets V, Wirtz S, Zeissig S, Zeissig Y, Bleich A, Baines JF. Analysis of factors contributing
727 to variation in the C57BL/6J fecal microbiota across german animal facilities. *Int J Med Microbiol*
728 [Internet]. 2016 Aug;306(5):343-55.
- 729 75. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. Critical role for MyD88-mediated neutrophil
730 recruitment during clostridium difficile colitis. *Infect Immun* [Internet]. 2012 ;80(9) :2989-96.
- 731 76. Ma KGL, Lertpiriyapong K, Piersigilli A, Dobtsis I, Wipf JRK, Littmann ER, Leiner I, Pamer EG,
732 Ricart Arbona RJ, Lipman NS. Outbreaks of typhlocolitis caused by hypervirulent group ST1
733 *clostridioides difficile* in highly immunocompromised strains of mice. *Comp Med* [Internet]. 2020 Jun
734 1;70(3):277-90.

- 735 77. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the
736 new delhi environment and its implications for human health: An environmental point prevalence study.
737 Lancet Infect Dis [Internet]. 2011 May;11(5):355-62.
- 738 78. Finley RL, Collignon P, Larsson DGJ, McEwen SA, Li X, Gaze WH, Reid-Smith R, Timinouni M,
739 Graham DW, Topp E. The scourge of antibiotic resistance: The important role of the environment. Clin
740 Infect Dis [Internet]. 2013 Sep;57(5):704-10.
- 741 79. Wellington EMH, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, Johnson-Rollings AS, Jones
742 DL, Lee NM, Otten W, Thomas CM, Williams AP. The role of the natural environment in the emergence
743 of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis [Internet]. 2013 Feb;13(2):155-65.
- 744 80. Fouz N, Pangesti KNA, Yasir M, Al-Malki A, Azhar EI, Hill-Cawthorne G, Abd El Ghany M. The
745 contribution of wastewater to the transmission of antimicrobial resistance in the environment: Implications
746 of mass gathering settings. Tropical medicine and infectious disease [Internet]. 2020;5(1):33.
- 747 81. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential
748 resistance in environmental sources: Potential public health implications. Molecules [Internet]. 2018 Mar
749 30;23(4):795. doi: 10.3390/molecules23040795.
- 750 82. Paulus GK, Hornstra LM, Alygizakis N, Slobodnik J, Thomaidis N, Medema G. The impact of on-site
751 hospital wastewater treatment on the downstream communal wastewater system in terms of antibiotics and
752 antibiotic resistance genes. Int J Hyg Environ Health [Internet]. 2019;222(4):635-44.
- 753 83. Anwar M, Iqbal Q, Saleem F. Improper disposal of unused antibiotics: An often-overlooked driver of
754 antimicrobial resistance. Expert Rev Anti Infect Ther [Internet]. 2020 Aug;18(8):697-9.
- 755 84. Meyer EL, Golston G, Thomaston S, Thompson M, Rengarajan K, Olinger P. Is your institution
756 disposing of culture media containing antibiotics? Applied Biosafety [Internet]. 2017;22(4):164-7.
- 757 85. Grabowski Ł, Gaffke L, Pierzynowska K, Cyske Z, Choszcz M, Węgrzyn G, Węgrzyn A.
758 Enrofloxacin-the ruthless killer of eukaryotic cells or the last hope in the fight against bacterial infections?
759 International journal of molecular sciences [Internet]. 2022;23(7):3648.

760 86. Ong KH, Khor WC, Quek JY, Low ZX, Arivalan S, Humaidi M, Chua C, Seow KLG, Guo S, Tay
761 MYF, Schlundt J, Ng LC, Aung KT. Occurrence, and antimicrobial resistance traits of escherichia coli
762 from wild birds and rodents in singapore. Int J Environ Res Public Health [Internet]. 2020 Aug
763 3;17(15):5606. doi: 10.3390/ijerph17155606.87.

764 87. Lü F, Wang W, Hu T, Duan H, Shao L, Zhang H, He P. Release of airborne antibiotic resistance genes
765 from municipal solid waste transfer stations. Sustainable Environment Research [Internet]. 2022;32(1):28.

766 88. Straumfors A, Eduard W, Andresen K, Sjaastad AK. Predictors for increased and reduced rat and
767 mouse allergen exposure in laboratory animal facilities. Ann Work Expo Health [Internet]. 2018 Oct
768 15;62(8):953-65.

769

770 **Data Availability Statement:** Data is available upon request to the corresponding author.

771 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the
772 design of the study; in the collection, analyses, or interpretation of the data; in the writing of the
773 manuscript; or in the decision to publish the results.

774

775

776

777

778

Figure 1.




Figure 2.




Figure 3.

"Polymyxin B sulphate + neomycin sulphate or enrofloxacin oral solution and amoxicillin in drinking water, post-irradiation."

"Metronidazole + amoxicillin in chow...amoxicillin + clarithromycin + metronidazole + omeprazole combination in feed for Helicobacter treatment in immunodeficient mice."

"...ampicillin + vancomycin + imipenem + metronidazole + ciprofloxacin in water (to reduce gastrointestinal biome)."

"...vancomycin, ampicillin, neomycin in oral gavage."

"Vancomycin, metronidazole, gentamicin, kanamycin, colistin, cefaclor, erythromycin in drinking water."

"Trimethoprim sulphonamide + oxytetracycline in food."

"...cephalexin and enrofloxacin."

medRxiv preprint doi: <https://doi.org/10.1101/2023.10.03.23296475>; this version posted October 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4.




Figure 5.

Methods of Disposal of Antimicrobial Containing Substrate




Figure 6.

Sources of Antimicrobials

